Sponsors (3)
The bill strengthens U.S. trade tools, staffing, transparency, and fast response options to protect American pharmaceutical companies and preserve access to innovative drugs, at the cost of higher potential domestic drug prices, diplomatic friction, and increased federal administrative expenses.
Patients with chronic conditions may retain better access to innovative U.S. medicines because the bill empowers the U.S. to pressure foreign governments and pursue enforcement that defends higher reimbursement for new drugs.
U.S. biopharma companies and taxpayers collectively benefit from preserved incentives for R&D because protecting higher prices and stronger enforcement can sustain returns that fund future drug development.
U.S. pharmaceutical manufacturers (including small firms and exporters) gain improved tools, a dedicated negotiator, and clearer documentation to pursue market access and challenge unfair foreign reimbursement practices.
U.S. patients and taxpayers could face higher domestic drug prices if the U.S. successfully pressures foreign governments to accept higher reimbursement or imposes trade remedies.
U.S. exporters, businesses, and taxpayers risk retaliatory trade measures and strained diplomatic relations (including from public naming of countries), which could raise costs and disrupt trade.
Federal agencies and taxpayers will face added administrative and staffing costs because expanding USTR roles, producing annual reports, and meeting rapid response deadlines increase workload and may require new resources.
Based on analysis of 5 sections of legislative text.
Creates a Chief Pharmaceutical Trade Negotiator at USTR, requires annual reports on high‑income countries' pharma pricing policies, and mandates 30‑day USTR response plans that may include Title III trade actions.
Official title: Identify and take action against international trade practices of high income countries that unfairly exploit innovation by deviating from market-based policies and unfairly exploit United States innovation, and for other purposes.
Introduced August 5, 2026 by Timothy Patrick Sheehy · Last progress August 5, 2026
Creates a new Chief Pharmaceutical Trade Negotiator inside the U.S. Trade Representative and directs USTR to monitor and report annually on pharmaceutical pricing and reimbursement policies in World Bank–classified high‑income countries. If USTR finds that a country’s policies materially harm U.S. market access, innovation incentives, or violate trade commitments, the agency must submit a response plan to Congress within 30 days and may initiate trade remedy or Title III actions. The bill frames mandatory low‑price reimbursement systems abroad as trade barriers that shift drug development costs to U.S. patients, and it requires public reporting, annual country lists, and formal USTR responses to objectionable foreign pharmaceutical pricing practices. It also adds coordinating language to USTR statute to establish the new position and to require consultation with the intellectual property trade negotiator as appropriate.